TRVI - Trevi Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.32
-0.24 (-2.86%)
As of 11:24AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.57
Open8.30
Bid8.32 x 1100
Ask8.59 x 1400
Day's Range8.30 - 8.50
52 Week Range5.69 - 10.62
Volume2,433
Avg. Volume134,836
Market Cap148.473M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-58.45
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.75
Trade prices are not sourced from all markets
  • GlobeNewswire11 days ago

    Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments

    Trevi Therapeutics, Inc. (TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced financial results for the quarter ended March 31, 2019, as well as recent business highlights. “The successful completion of our IPO enables Trevi to continue development of nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease,” said Jennifer L. Good, President and CEO of Trevi Therapeutics.

  • Benzinga21 days ago

    BMO Sees Compelling Valuation For Trevi Therapeutics At Current Levels

    Trevi's key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism of treating various chronic pruritus and cough conditions, analyst Nachman said in a Monday morning note. The pipeline asset has shown positive clinical data in a large Phase 2b/3 trial in uremic pruritus associated with chronic kidney disease, and in a smaller Phase 2 study in prurigo nodularis, the lead indication, the asset achieved statistical significance in a post-hoc analysis for patients who completed the study on the higher dose, Nachman noted. The analyst said prurigo nodularis is an area of high unmet need with a sizeable market opportunity.

  • GlobeNewswire2 months ago

    Trevi Therapeutics Announces Pricing of Initial Public Offering

    Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at an initial public offering price of $10.00 per share, for gross proceeds of $55 million. In addition, Trevi has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by Trevi.

  • Benzinga2 months ago

    Trevi Therapeutics IPO: What You Need To Know

    Trevi Therapeutics, Inc. will issue nearly 4.7 million shares on the Nasdaq under ticker TRVI, according to the firm’s S-1 filing. Lead underwriters include SVB Leerink, Stifel and BMO Capital Markets. The Connecticut biotech targets chronic pruritis, chronic cough related to idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia related to Parkinson’s disease.